Statements (56)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:acquisition |
gptkb:Sandoz
2005 |
| gptkbp:CEO |
gptkb:Richard_D._Smith
|
| gptkbp:employees |
approximately 1,500
|
| gptkbp:establishedIn |
gptkb:Germany
|
| gptkbp:founded |
1986
|
| gptkbp:founder |
gptkb:Wolfgang_W._Wiegand
|
| gptkbp:headquarters |
gptkb:Holzkirchen,_Germany
|
| https://www.w3.org/2000/01/rdf-schema#label |
Hexal AG
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:market |
Europe
|
| gptkbp:operatesIn |
gptkb:Germany
|
| gptkbp:parentCompany |
Novartis
|
| gptkbp:productLine |
antibiotics
antivirals hormone replacement therapy antihistamines dietary supplements anticoagulants antifungals antiparasitics vaccines probiotics antidepressants oral contraceptives antipsychotics analgesics antihypertensives nutraceuticals sedatives oncology drugs immunosuppressants stimulants antiemetics anticonvulsants cardiovascular drugs respiratory drugs dermatological drugs gastrointestinal drugs pain management drugs laxatives muscle relaxants antidiabetics anti-inflammatories antidiarrheals central nervous system drugs hormonal drugs ophthalmic drugs antimigraine_drugs |
| gptkbp:products |
generic drugs
|
| gptkbp:revenue |
€1 billion (approx.)
|
| gptkbp:specialization |
generic pharmaceuticals
|
| gptkbp:subsidiary |
gptkb:Sandoz_GmbH
|
| gptkbp:type |
public company
|
| gptkbp:website |
www.hexal.com
|